Slide 1: BioSyent Inc. Q3 / YTD 2023 Results
BioSyent Inc. Q3 / YTD 2023 Results NOVEMBER 16, 2023 PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX
Slide 4: Q3 / YTD 2023 Sales Summary ($)
Q3 / YTD 2023 Sales Summary ($) Q3 ‘23 Q3 ‘23 vs. YTD ‘23 YTD ‘23 vs. Sales ($) Q3 ’22 (%) Sales ($) YTD ’22 (%) Canadian Pharma ($) $7,432k +17% $21,566k +14% FeraMAX® Pd +17% +14% Tibella® +61% +50% Combogesic® (54%) (37%) RepaGyn® +12% +1% Inofolic® n/a n/a Cathejell® +4% +3% International Pharma
Slide 5: Sales, EBITDA and NIAT - Q3 2023
Sales, EBITDA and NIAT Quarter (Q3) ended September 30, 2023 9,000 +31% Sales +17% Canadian Pharma 8,000 +35% +100% International Pharma +2% +6% Legacy 7,000 +16% 6,000 EBITDA / NIAT • EBITDA Margin Q3 2023: 33% to Sales CAD (000's) 5,000 Q3 2022: 29% to Sales 4,000 +49% • NIAT Margin 3,000 +64% +62
Slide 6: Sales, EBITDA and NIAT - Nine Months 2023
Sales, EBITDA and NIAT Nine Months (YTD) ended September 30, 2023 25,000 +14% Sales +29% -4% +35% +14% Canadian Pharma 20,000 +76% International Pharma (19%) Legacy 15,000 EBITDA / NIAT CAD (000's) • EBITDA Margin YTD 2023: 27% to Sales 10,000 YTD 2022: 29% to Sales +38% -5% +7% • NIAT Margin +18% 5
Slide 7: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS 53 Consecutive Profitable Quarters Q3 2023 $2,350,900 $0.20 to Q3 2023 Q2 2023 $1,483,190 $0.12 $0.50 Q1 2023 $1,175,246 $0.10 Q4 2022 $1,199,516 $0.09 Q3 2022 $1,453,042 $0.12 Q2 2022 $1,217,883 $0.10 $0.49 Q1 2022 $1,587,904 $0.13 Q4 2021 $
Slide 8: 13 Years of Profitable Growth (and Counting!)
13 Years of Profitable Growth (and Counting!) 35,000 Annual Revenue Annual NIAT 30,000 25,000 CAD 000'S 20,000 15,000 10,000 5,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 *2023* f/d shares: 14,336,194 12,191,780 8 | www.biosyent.com | TSXV: RX
Slide 9: Q3 2023 Highlights
Q3 2023 Highlights ▪ Promotion of Gelclair® commenced ▪ New Inofolic® product for Polycystic Ovary Syndrome (PCOS) launched ▪ 4th consecutive quarterly dividend of $0.04 paid ▪ 80,000 shares repurchased under NCIB Subsequent to Q3 2023 ▪ menopauseinformation.ca launched ▪ Distribution of Gelclair® Q
Slide 10: Most recommended iron supplement in Canada
▪ Most recommended iron supplement in Canada - pharmacists and physicians - 8 consecutive years(1) ▪ Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2022 Survey on OTC Counselling and Recomme
Slide 11: FeraMAX LifeCycle Strategy
FeraMAX® LifeCycle Strategy ▪ Expanding leadership of FeraMAX® brand in Canada: “Iron health for life” ▪ FeraMAX® Pd platform introduced in October 2020 ▪ Patented delivery system based on Polydextrose Iron Complex (PDIC) ▪ Foundation for future product development ▪ Incremental share and revenue ▪
Slide 12: NEW in 2023 - FeraMAX Pd Maintenance 45
NEW in 2023 - FeraMAX® Pd Maintenance 45 ▪ Developed by BioSyent ▪ 3rd product incorporating PDIC ▪ Designed to: ▪ prevent iron deficiency ▪ maintain healthy iron levels ▪ Unique formulation: ▪ chewable ▪ pleasant taste ▪ 45 mg elemental iron ▪ supportive vitamins for iron health ▪ Launched in Canad
Slide 13: NEW in 2023 - Inofolic
NEW in 2023 - Inofolic® ▪ In-licensed by BioSyent in October 2020 ▪ New treatment option for women with Polycystic Ovary Syndrome (PCOS), an endocrine disorder which can cause: ▪ Insulin resistance ▪ Infertility ▪ Menstrual dysfunction ▪ Skin manifestations ▪ Hirsutism ▪ Alopecia ▪ Unique soft-gel c
Slide 14: NEW in 2023 - Gelclair
NEW in 2023 - Gelclair® ▪ In-licensed by BioSyent in December 2022 ▪ Oncology supportive care product for relief of oral mucositis ▪ Frequently experienced by cancer patients undergoing radiation or chemotherapy ▪ Protective concentrated gel which adheres to the mucosa of the mouth, providing: ▪ Fas
Slide 15: Growth Drivers
Growth Drivers Management of symptoms of PCOS Oncology supportive care product for Oral Mucositis FeraMAX® Pd Platform – Life Cycle Strategy In development HRT agent for menopause therapy Acquisition and in-licensing – ongoing 15 | www.biosyent.com | TSXV: RX
Slide 16: Cash Balance & Return on Equity
Cash Balance & Return on Equity (“RoE”) 30,000 19% • Zero Debt 19% 29,290 19% 28,000 19% • TTM Sept 30/23 Cash from 27,785 27,102 Operations of $6.5M 26,000 19% 18% • TTM Sept 30/23 NCIB share 24,000 buybacks: $2.7M CAD (000's) RoE % 18% 22,000 18% 18% • TTM Sept 30/23 Dividends of 18% $1.9M 18% 20,
Slide 17: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification Cash: Dividends $29.3M Growth & Diversification Debt: Share $0M Buybacks Excess capital may also be returned to shareholders: • $0.04/share quarterly Dividend – Q4’22 – Q4’23 = $ 2.4
Slide 18: Stock Information
Stock Information – TO BE UPDATED As at November 13, 2023 Exchange & Trading Symbol 0% TSXV: RX Nov 13, 2023 Closing Stock Price (CAD) $8.21 52 Week Hi/Low: $8.21 / $6.51 Issued Common Shares: 12,031,961 Treasury – RSU Shares in Trust (207,343) Outstanding Common Shares: 11,824,618 Options Outstandi
Slide 19: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 19 | www.biosyent.com | TSXV: RX